International Flavors & Fragrances (IFF) has announced the appointment of Frank Clyburn as CEO and member of the board of directors, effective 14 February 2022.
Clyburn, who will step down from his position as executive VP and president of human health at Merck & Co, succeeds current IFF CEO Andreas Fibig. Clyburn has experience in R&D, mergers & acquisitions, and brings with him the ability to connect with customers and stakeholders on numerous levels.
Clyburn said: “I am honoured to serve as IFF’s next CEO. This is an iconic company and industry leader with tremendous opportunity to deliver outstanding customer experience and long-term, sustainable growth. The purpose and vision of IFF is very closely linked with accelerating global trends of nutrition, wellness and sustainability, which means that together, colleagues around the world can deliver significant value for both customers and shareholders. Working with IFF’s world-class talent, unrivalled offerings and impressive innovation platform, I am excited to bring my approach to executional excellence to capitalise on IFF’s bright future.”
“Frank is the best executive to lead IFF into its next chapter at the pace we need. His strong operating experience plus his hands-on approach and customer-centric perspective will accelerate the execution of IFF’s strategic and operating priorities,” added Dale Morrison, IFF director.
The company has also announced that it will separate its CEO and chairman roles. Morrison, long-standing IFF director, will assume the position of non-executive chairman of the board, also effective 14 February.
By Sian Yates
A report from ingredients supplier Henley Bridge has warned that cocoa price increases of 15-20% for the first half of 2024 might continue into the second half of the year. Despite growth in global cocoa supply in 2021, unfavourable weather conditions and demand from emerging markets have led to supply deficits.
By carving out the ANH business, DSM-Firmenich would focus fully on its Perfumery & Beauty; Taste, Texture & Health; and Health, Nutrition & Care divisions. Full focus on these businesses is expected to enhance commercial potential and synergies, supporting “consistent growth outlook alongside robust margins”.
Cargill and Enough are expanding their partnership to further develop nutritious and sustainable alternative meat and dairy solutions. Cargill has signed a commercial agreement to use and market Enough’s Abunda protein and has also invested in the company’s Series C growth funding round.